Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.61 |
| ▸ | SRC | P12931 | 11/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 11/20 | 0.52 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | BCR | P11274 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5040071 | 0.85 | EGFR (0.61) | EGFRSRCKCNH2KDRBRAF | |
| SCHEMBL14353338 | 0.83 | EGFR (0.53) | EGFRSRCKCNH2KDRFGFR1 | |
| SCHEMBL6365282 | 0.77 | EGFR (0.47) | EGFRSRCKCNH2KDRFGFR1 | |
| SCHEMBL4466493 | 0.76 | EGFR (1.00) | EGFRSRCKCNH2KDRBRAF | |
| SCHEMBL4156436 | 0.75 | ALDH1A1 (0.44) | EGFRSRCKDRFGFR1FLT1 | |
| SCHEMBL3568126 | 0.73 | EGFR (0.69) | EGFRSRCKCNH2KDRBRAF | |
| SCHEMBL6519244 | 0.72 | KDR (0.59) | EGFRKCNH2KDRFGFR1FLT1 | |
| SCHEMBL20355385 | 0.72 | EGFR (0.60) | EGFRSRCKCNH2KDRFLT1 | |
| SCHEMBL12474212 | 0.72 | EGFR (0.64) | EGFRSRCKCNH2KDRBRAF | |
| SCHEMBL3740944 | 0.70 | SRC (0.83) | EGFRSRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080573-B2 | Heterocycle substituted amide and sulfur amide derivatives as histone deacetylase (hdac) inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-12-20 | — | — | US | disclosed |
| US-20090156619-A1 | Heterocycle Substituted Amide and Sulfur Amide Derivatives as Histone Deacetylase (HDAC) Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156619-A1 | Heterocycle Substituted Amide and Sulfur Amide Derivatives as Histone Deacetylase (HDAC) Inhibitors | HDAC1, HDAC6, HDAC11 | EGFR 2450/4885SRC 477/4885KCNH2 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.